Shares of GPC Biotech AG have begun to recover after the company announced that it was withdrawing its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for accelerated approval of its cancer-drug candidate, satraplatin.
Shares of GPC Biotech AG have begun to recover after the company announced that it was withdrawing its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for accelerated approval of its cancer-drug candidate, satraplatin.